Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20+ Follicular Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00742144
What this trial is testing

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
GlaxoSmithKline 6
Early research (Phase 1)Study completedNCT00556699
What this trial is testing

SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Genentech, Inc. 22
Not applicableStudy completedNCT04918940
What this trial is testing

Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma

Who this might be right for
Follicular LymphomaMantle Cell Lymphoma
Centre Henri Becquerel 20
Large-scale testing (Phase 3)Study completedNCT00278421
What this trial is testing

Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group 592
Testing effectiveness (Phase 2)WithdrawnNCT00003663
What this trial is testing

Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT00071955
What this trial is testing

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Genitope Corporation
Large-scale testing (Phase 3)Study completedNCT01724021
What this trial is testing

Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Who this might be right for
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Hoffmann-La Roche 743
Large-scale testing (Phase 3)Study completedNCT01609010
What this trial is testing

MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Who this might be right for
Lymphoma
Hoffmann-La Roche 313
Early research (Phase 1)Study completedNCT01680991
What this trial is testing

Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Who this might be right for
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Hoffmann-La Roche 48
Early research (Phase 1)Study completedNCT00354926
What this trial is testing

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Applied Molecular Evolution 67
Testing effectiveness (Phase 2)Study completedNCT00251394
What this trial is testing

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Dana-Farber Cancer Institute 30
Not applicableEnrolling By InvitationNCT06985576
What this trial is testing

Long-term Study to Evaluate Safety and Persistence of GF-CART01

Who this might be right for
DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma (FL)Primary Mediastinal Large B-Cell Lymphoma+1 more
GenomeFrontier Therapeutics TW Co., Ltd. 18
Testing effectiveness (Phase 2)Ended earlyNCT02384954
What this trial is testing

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Altor BioScience 43
Testing effectiveness (Phase 2)Ended earlyNCT00493454
What this trial is testing

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 6
Early research (Phase 1)Study completedNCT02290951
What this trial is testing

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Who this might be right for
Non-Hodgkin LymphomaChronic Lymphocytic Leukemia
Regeneron Pharmaceuticals 200
Testing effectiveness (Phase 2)Study completedNCT00596804
What this trial is testing

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's LymphomaLymphoma, DiffuseLymphoma, Diffuse, Mixed Lymphocytic-Histiocytic
Gilead Sciences 39
Testing effectiveness (Phase 2)Study completedNCT00005601
What this trial is testing

Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Alliance for Clinical Trials in Oncology 58
Testing effectiveness (Phase 2)Ended earlyNCT00625729
What this trial is testing

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Masonic Cancer Center, University of Minnesota 6
Early research (Phase 1)Study completedNCT00244946
What this trial is testing

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Barbara Ann Karmanos Cancer Institute 15
Early research (Phase 1)Study completedNCT00110071
What this trial is testing

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt Lymphoma+12 more
Fred Hutchinson Cancer Center 38
Next Page